Salirasib

Drug Profile

Salirasib

Alternative Names: KD 032; ONO-7056; S-Farnesylthiosalicyclic acid; Transfarnesylthiosalicyclic acid

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Concordia Pharmaceuticals
  • Developer Concordia Pharmaceuticals; Johns Hopkins University; Kadmon Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Ono Pharmaceutical
  • Class Antineoplastics; Benzoic acids; Sulfides
  • Mechanism of Action MTOR protein inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 31 Oct 2015 Discontinued - Phase-I for Solid tumours in Japan (PO)
  • 15 Jun 2015 Discontinued - Phase-I for Colorectal cancer in USA (PO)
  • 15 Jun 2015 Discontinued - Phase-I/II for Pancreatic cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top